Corline Biomedical AB (CLBIO) - Net Assets
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has net assets worth Skr99.00 Million SEK (≈ $10.65 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr114.18 Million ≈ $12.29 Million USD) and total liabilities (Skr15.18 Million ≈ $1.63 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CLBIO strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr99.00 Million |
| % of Total Assets | 86.7% |
| Annual Growth Rate | 38.4% |
| 5-Year Change | 1.65% |
| 10-Year Change | 141.98% |
| Growth Volatility | 142.32 |
Corline Biomedical AB - Net Assets Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Corline Biomedical AB.
Annual Net Assets for Corline Biomedical AB (2012–2025)
The table below shows the annual net assets of Corline Biomedical AB from 2012 to 2025. Also explore net asset growth rate of Corline Biomedical AB to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr93.76 Million ≈ $10.09 Million |
+7.88% |
| 2024-12-31 | Skr86.91 Million ≈ $9.35 Million |
-6.86% |
| 2023-12-31 | Skr93.32 Million ≈ $10.04 Million |
-1.35% |
| 2022-12-31 | Skr94.59 Million ≈ $10.18 Million |
+2.55% |
| 2021-12-31 | Skr92.23 Million ≈ $9.93 Million |
+77.26% |
| 2020-12-31 | Skr52.03 Million ≈ $5.60 Million |
-12.28% |
| 2019-12-31 | Skr59.32 Million ≈ $6.38 Million |
+7.93% |
| 2018-12-31 | Skr54.96 Million ≈ $5.91 Million |
+19.68% |
| 2017-12-31 | Skr45.93 Million ≈ $4.94 Million |
+18.53% |
| 2016-12-31 | Skr38.75 Million ≈ $4.17 Million |
+82.33% |
| 2015-12-31 | Skr21.25 Million ≈ $2.29 Million |
+287.44% |
| 2014-12-31 | Skr5.48 Million ≈ $590.25K |
-31.41% |
| 2013-12-31 | Skr8.00 Million ≈ $860.60K |
+482.77% |
| 2012-12-31 | Skr1.37 Million ≈ $147.67K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Corline Biomedical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15256840200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr3.20 Million | 3.41% |
| Other Comprehensive Income | Skr54.92 Million | 58.57% |
| Other Components | Skr199.41 Million | 212.68% |
| Total Equity | Skr93.76 Million | 100.00% |
Corline Biomedical AB Competitors by Market Cap
The table below lists competitors of Corline Biomedical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unlu Yatirim Holding AS
IS:UNLU
|
$41.49 Million |
|
GiG Software PLC
ST:GIG-SDB
|
$41.49 Million |
|
Jetbest
TWO:4741
|
$41.51 Million |
|
Ekso Bionics Holdings Inc
NASDAQ:EKSO
|
$41.51 Million |
|
UNITEKNO Co.Ltd
KQ:241690
|
$41.46 Million |
|
German High Street Properties A/S Class B
CO:GERHSP
|
$41.45 Million |
|
Enra Group Bhd
KLSE:8613
|
$41.44 Million |
|
Globalink Investment Inc
NASDAQ:GLLI
|
$41.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Corline Biomedical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 86,914,000 to 93,759,000, a change of 6,845,000 (7.9%).
- Net loss of 14,714,000 reduced equity.
- Share repurchases of 21,559,000 reduced equity.
- New share issuances of 21,559,000 increased equity.
- Other comprehensive income decreased equity by 5,667,000.
- Other factors increased equity by 27,226,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-14.71 Million | -15.69% |
| Share Repurchases | Skr21.56 Million | -22.99% |
| Share Issuances | Skr21.56 Million | +22.99% |
| Other Comprehensive Income | Skr-5.67 Million | -6.04% |
| Other Changes | Skr27.23 Million | +29.04% |
| Total Change | Skr- | 7.88% |
Book Value vs Market Value Analysis
This analysis compares Corline Biomedical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.89x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 250.56x to 3.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.06 | Skr14.75 | x |
| 2013-12-31 | Skr0.81 | Skr14.75 | x |
| 2014-12-31 | Skr0.55 | Skr14.75 | x |
| 2015-12-31 | Skr2.41 | Skr14.75 | x |
| 2016-12-31 | Skr3.20 | Skr14.75 | x |
| 2017-12-31 | Skr3.37 | Skr14.75 | x |
| 2018-12-31 | Skr3.53 | Skr14.75 | x |
| 2019-12-31 | Skr3.54 | Skr14.75 | x |
| 2020-12-31 | Skr3.03 | Skr14.75 | x |
| 2021-12-31 | Skr4.51 | Skr14.75 | x |
| 2022-12-31 | Skr4.40 | Skr14.75 | x |
| 2023-12-31 | Skr4.30 | Skr14.75 | x |
| 2024-12-31 | Skr3.98 | Skr14.75 | x |
| 2025-12-31 | Skr3.79 | Skr14.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Corline Biomedical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -192.31%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.05x
- Recent ROE (-15.69%) is above the historical average (-27.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -155.88% | -15.19% | 0.48x | 21.31x | Skr-969.94K |
| 2013 | -31.11% | -139.17% | 0.13x | 1.72x | Skr-3.29 Million |
| 2014 | -45.80% | -149.25% | 0.10x | 3.06x | Skr-3.06 Million |
| 2015 | -27.51% | -563.62% | 0.04x | 1.18x | Skr-7.97 Million |
| 2016 | -13.54% | -554.17% | 0.02x | 1.07x | Skr-9.12 Million |
| 2017 | -17.01% | -1224.14% | 0.01x | 1.12x | Skr-12.40 Million |
| 2018 | -12.36% | -434.61% | 0.02x | 1.14x | Skr-12.29 Million |
| 2019 | -16.08% | -896.62% | 0.02x | 1.07x | Skr-15.47 Million |
| 2020 | -14.00% | -197.16% | 0.06x | 1.12x | Skr-12.49 Million |
| 2021 | -7.50% | -97.93% | 0.07x | 1.10x | Skr-16.14 Million |
| 2022 | 2.46% | 9.89% | 0.23x | 1.08x | Skr-7.13 Million |
| 2023 | -1.94% | -7.23% | 0.25x | 1.07x | Skr-11.14 Million |
| 2024 | -26.69% | -237.28% | 0.10x | 1.09x | Skr-31.89 Million |
| 2025 | -15.69% | -192.31% | 0.08x | 1.05x | Skr-24.09 Million |
Industry Comparison
This section compares Corline Biomedical AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $48,330,800
- Average return on equity (ROE) among peers: -134.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Corline Biomedical AB (CLBIO) | Skr99.00 Million | -155.88% | 0.15x | $41.48 Million |
| 2cureX AB (2CUREX) | $13.62 Million | -53.33% | 0.76x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $111.73 Million | -21.83% | 0.04x | $7.82 Million |
| AcouSort AB (ACOU) | $8.46 Million | -178.16% | 0.46x | $6.29 Million |
| Active Biotech AB (ACTI) | $22.11 Million | -145.24% | 0.45x | $11.91 Million |
| Alzinova AB (ALZ) | $121.96 Million | -21.54% | 0.18x | $9.10 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $95.97 Million |
| Annexin Pharmaceuticals AB (ANNX) | $13.71 Million | -366.46% | 0.39x | $9.68 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $2.35 Million |
| BioInvent International AB (BINV) | $29.45 Million | -307.87% | 0.85x | $158.63 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.60 Billion |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent ha… Read more